Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Acadia Pharmaceuticals' Stock Is Soaring Today

By George Budwell - Mar 28, 2016 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The moment of truth is nearing for the biopharma's Parkison's disease drug, Nuplazid.

Image source: Flickr via user jonel hanopol.

What: Shares of Acadia Pharmaceuticals (ACAD -0.91%) gained more than 20% in early morning trading today on exceptionally high volume. The apparent catalyst behind this move upward was a positive note in the FDA's briefing documents for the company's experimental Parkinson's disease psychosis (PDP) drug called Nuplazid (pimavanserin), which is scheduled to be reviewed by a panel of outside experts tomorrow. Specifically, the agency noted in its internal review: 

Although the Division usually requires evidence of efficacy from more than one positive, adequate, and well-controlled trial, it is within our authority to rely on one robustly positive trial, especially when we have supportive evidence from the early part of the development program.

So what: Short-sellers have been piling into Acadia ahead of Nuplazid's regulatory review, presumably because the drug has failed to meet its primary endpoint in three of its clinical trials and only hit the mark in a single late-stage study.  

ACAD Chart

ACAD data by YCharts.

Now what: The FDA is expected to hand down Nuplazid's regulatory decision by May 1. As there are no approved treatments for PDP at the moment, some analysts think Nuplazid could generate peak sales in excess of $3 billion if approved. So, Acadia's shareholders will clearly want to pay close attention to tomorrow's review.

In light of the fact that most, if not all, of Acadia's valuation is built on Nuplazid's commercial potential, though, I personally won't be picking up any shares in this speculative biopharma until this significant regulatory risk is off the table.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
ACAD
$14.09 (-0.91%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.